Search

Search Constraints

You searched for: Author/Creator Barrans, S.

Search Results

2. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019)

3. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019)

4. CROSS‐PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN a CLINICAL LABORATORY SETTING. (June 2017)

6. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL‐B. (June 2017)

7. DNMT3A‐2 EXPRESSION LEVELS CHARACTERISE DIFFUSE LARGE B‐CELL LYMPHOMA WITH DISTINCT METHYLATION PATTERNS AND OUTCOME. (June 2017)

8. GENE EXPRESSION PROFILING AND MUTATION ANALYSIS CAN AID TREATMENT DECISION MAKING IN AGGRESSIVE B CELL LYMPHOMA PATIENTS. (June 2017)

9. HIGH EXPRESSION OF BCL‐2 AND BCL‐XL IN DIFFUSE LARGE B‐CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS. (12th June 2019)

10. Identifying somatic mutations in cell‐free DNA of aggressive lymphoma patients: First cell‐free DNA results from the molecular profiling for lymphoma (MaPLe) study. (June 2017)